On October 6, 2020 AbbVie (NYSE: ABBV)reported that it will announce its third-quarter 2020 financial results on Friday, October 30, 2020, before the market opens (Press release, AbbVie, OCT 6, 2020, View Source [SID1234568139]). AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 6, 2020 Elthera reported that it has been awarded a non-dilutive grant from the Swiss Innovation Agency (Innosuisse) with a total budget of more than CHF 1.0 M. In collaboration with the Institute of Oncology Research (IOR) in Bellinzona (Switzerland), Elthera will use the grant to validate the target L1CAM in rare types of cancer (Press release, Elthera, OCT 6, 2020, View Source;utm_medium=rss&utm_campaign=elthera-and-the-institute-of-oncology-research-in-bellinzona-receive-innosuisse-grant [SID1234568135]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Gunther Spohn, CSO of Elthera, commented: "We are excited to initiate this collaboration with IOR, one of the most renowned cancer research organizations in Switzerland. The Innosuisse funds will allow us to explore the therapeutic potential of our anti-L1CAM compounds in rare types of cancer, which are not adequately treated with current therapies. By combining Elthera’s knowledge in the development of therapeutic antibodies and IOR’s expertise in basic and translational research in rare cancer types we aim to develop new efficacious immunotherapies for diseases, which are often neglected by global drug development companies."

Prof. Francesco Bertoni, Deputy Director of IOR, commented: "The collaboration with Elthera will allow us to elucidate the role of L1CAM in the development and progression of rare malignancies, where a high medical need for better treatment exists. By elucidating L1CAM-dependent disease mechanisms and establishing the efficacy of Elthera’s anti-L1CAM compounds in preclinical disease models, we aim to lay the ground for new and better therapies for the affected patients."

On October 6, 2020 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019 (Press release, Halozyme, OCT 6, 2020, View Source [SID1234568134]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the newly announced expansion, argenx gained the ability to exclusively access Halozyme’s ENHANZE drug delivery technology for three additional targets upon nomination for a total of up to six targets under the existing and newly expanded collaboration. To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn and complement component C2.

"We are pleased to be expanding the scope of our collaboration with Halozyme and to continue our productive relationship. We recognize that patients have different preferences and we want to secure our ability to offer subcutaneous delivery of our current and future candidates to reach as many patients as possible. We already have exclusive access to ENHANZE for our FcRn antagonist efgartigimod, which is in late stage development for multiple severe autoimmune diseases, and additionally have nominated our complement inhibitor targeting C2," said Keith Woods, Chief Operating Officer of argenx.

"We are delighted that argenx has agreed to expand our global collaboration and license agreement to include up to six targets," said Dr. Helen Torley, president and chief executive officer. "argenx has made rapid progress in the clinic with efgartigimod utilizing ENHANZE since signing the original agreement, moving to a Phase 2 study initiation for an indication being developed only as SC, within just fourteen months. argenx is also working to bring SC efgartigimod to patients suffering from myasthenia gravis following the successful ADAPT trial results."

On October 6, 2020 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that it has entered into a license agreement with argenx that grants argenx worldwide non-exclusive rights for Chugai’s antibody engineering technologies (Press release, Chugai, OCT 6, 2020, View Source [SID1234568132]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, argenx will receive the rights to use two Chugai’s antibody engineering technologies (SMART-Ig and ACT-Ig) for their research activities, and option to develop and market therapeutic antibodies applying those technologies. In return for the license, Chugai will receive a fee for technology access. In case argenx creates a candidate antibody and exercises the option, Chugai will receive upfront payment, milestone payment according to the development status, and royalty payment if the compound is launched as an approved antibody drug.

On October 6, 2020 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported that Halozyme and argenx are expanding their existing global collaboration and license agreement that was signed in February 2019 (Press release, Halozyme, OCT 6, 2020, View Source [SID1234568121]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the newly announced expansion, argenx gained the ability to exclusively access Halozyme’s ENHANZE drug delivery technology for three additional targets upon nomination for a total of up to six targets under the existing and newly expanded collaboration. To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn and complement component C2.

"We are pleased to be expanding the scope of our collaboration with Halozyme and to continue our productive relationship. We recognize that patients have different preferences and we want to secure our ability to offer subcutaneous delivery of our current and future candidates to reach as many patients as possible. We already have exclusive access to ENHANZE for our FcRn antagonist efgartigimod, which is in late stage development for multiple severe autoimmune diseases, and additionally have nominated our complement inhibitor targeting C2," said Keith Woods, Chief Operating Officer of argenx.

"We are delighted that argenx has agreed to expand our global collaboration and license agreement to include up to six targets," said Dr. Helen Torley, president and chief executive officer. "argenx has made rapid progress in the clinic with efgartigimod utilizing ENHANZE since signing the original agreement, moving to a Phase 2 study initiation for an indication being developed only as SC, within just fourteen months. argenx is also working to bring SC efgartigimod to patients suffering from myasthenia gravis following the successful ADAPT trial results."